AMPRENAVIR manufacturers and suppliers in india

AMPRENAVIR

Properties

Melting point:: 72-74°C

Density: 1.30±0.1 g/cm3(Predicted)

storage temp.: -20°C

solubility: DMSO: soluble20mg/mL, clear

form: powder

pka: 11.54±0.46(Predicted)

color: white to beige

optical activity: [α]/D +8 to +12°, c = 0.5 in methanol

BCS Class: 2

InChIKey: YMARZQAQMVYCKC-OEMFJLHTSA-N

Safety Information

Symbol(GHS): GHS07

Signal word: Warning

Hazard statements: H302-H315-H319-H332-H335

Precautionary statements: P261-P280-P305+P351+P338

RIDADR: 3077

WGK Germany: 3

HS Code: 29350090

Use

Amprenavir was launched as Agenerase in the US for the treatment of AIDS patients in combination with approved agent antiretroviral nucleoside analogs. It is the fifth non-peptidic inhibitor of HIV-1 protease to be marketed in this indication after the last approved Neflinavir. Amprenavir, designed via a structure-based process, is the smallest molecule in the 《navir》 class and exhibits a reduced peptidic character. An improved process for preparation comprising four steps from a (1S, 2R)-2-hydroxy-3-aminopropylcarbamate has been developed. Amprenavir is a potent inhibitor of HIV-1 aspartyl protease (Ki = 0.6nM), an enzyme required by the virus to cleave pro-form polyproteins to structural proteins during the last stage in the replication process. The compound displays good oral bioavailability in humans and penetrates the CNS, which is an important advantage in long-term treatment. Its plasma half-life is approximately 10h. Treatment with Amprenavir in combination with nucleoside analog reverse transcriptase inhibitors considerably decreases viral load and restores CD4+ T-cell counts in patients with HIV infection.